Buy Stocks Easy | About Us
January 25, 2022
Buy Stocks Easy | Online Stocks

NBRV


Buy Nabriva Therapeutics plc Stock (symbol: NBRV) Easy Online

Company Name: Nabriva Therapeutics plc

Symbol: NBRV

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2015

NBRV Current Share Price

Today's NBRV ( Nabriva Therapeutics plc ) opening price: $1.4000

Yesterday's NBRV ( Nabriva Therapeutics plc ) closing price: $1.7200

Nabriva Therapeutics plc Stock ( symbol: NBRV ) Price Chart since IPO (2015):

12 Months Nabriva Therapeutics plc Stock ( symbol: NBRV ) Price Chart

Popular Questions about Nabriva Therapeutics plc Public Stock ( NBRV )

A: Nabriva Therapeutics plc stock symbol (also called stock or share ticker) is NBRV

A: Nabriva Therapeutics plc IPO (Initial Public Offering) took place on 2015

A: Nabriva Therapeutics plc's stock (NBRV symbol) price at ther IPO (initial Public Offering) was $1.4000

Q: Is NBRV stock worth buying at the moment?

A: The NBRV stock performance since 2019 are rather disappointing. If you had bought 1 share of Nabriva Therapeutics plc stock (symbol: NBRV) at the beginning of 2019, at the opening share price of $1.9000, you would be left with exactly $1.4000 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy Nabriva Therapeutics plc Stock Easy Online

Nabriva Therapeutics plc Stock Ticker Price Chart since IPO:





Nabriva Therapeutics plc Stock Price Yesterday



 


Nabriva Therapeutics plc Stock Price – Last Week




 


Nabriva Therapeutics plc Stock Price – Last Month




 


Nabriva Therapeutics plc Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/02/1955075/0/en/Nabriva-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
                            

                                
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

                                
                                
DUBLIN, Ireland, Dec.  02, 2019  (GLOBE NEWSWIRE) -- Nabriva Therap...


                            

                        
                    

                


                            

                    


                        
                            https://www.benzinga.com/general/biotech/19/11/14805019/biotech-stock-on-the-radar-nabriva-and-its-novel-antibiotic-portfolio
                            

                                
Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio

                                
                                
Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) shares have gained ab...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4306054-nabriva-therapeutics-plc-nbrv-ceo-ted-schroeder-q3-2019-results-earnings-call-transcript
                            

                                
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q3 2019 Results - Earnings Call Transcript

                                
                                
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q3 2019 Result...


                            

                        
                    

                


                            

                    


                        
                            https://investorplace.com/2019/10/7-strong-buy-stocks-with-triple-digit-growth-prospects/
                            

                                
7 “Strong Buy” Stocks With Triple-Digit Growth Prospects

                                
                                
Investors want to know which stocks are set to take flight. We are ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/15/1929549/0/en/Nabriva-to-Present-Data-at-the-CHEST-Annual-Meeting-Demonstrating-the-Safety-and-Efficacy-of-Newly-FDA-Approved-XENLETA-lefamulin-for-the-Treatment-of-Community-Acquired-Bacterial-.html
                            

                                
Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

                                
                                
Poster sessions to highlight pooled results from the pivotal LEAP 1...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/27/1921983/0/en/Lefamulin-Evaluation-Against-Pneumonia-2-LEAP-2-Study-Results-Published-in-the-Journal-of-the-American-Medical-Association.html
                            

                                
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association

                                
                                
Nabriva publication of Phase 3 clinical trial results highlights ef...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/26/1921564/0/en/Nabriva-to-Present-Data-from-XENLETA-lefamulin-and-CONTEPO-fosfomycin-Development-Programs-at-IDWeek-2019.html
                            

                                
Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019

                                
                                
DUBLIN, Ireland, Sept.  26, 2019  (GLOBE NEWSWIRE) -- Nabriva Thera...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4293576-lowdown-nabriva
                            

                                
The Lowdown On Nabriva

                                
                                
Today, we look at Nabriva Therapeutics which has received a tepid r...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/18/1917242/0/en/Nabriva-Therapeutics-to-Present-at-the-2019-Cantor-Global-Healthcare-Conference.html
                            

                                
Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

                                
                                
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept.  18, 2019  (GLOBE N...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/09/1912634/0/en/Nabriva-s-XENLETA-lefamulin-for-the-Treatment-of-Community-Acquired-Bacterial-Pneumonia-CABP-Now-Available-in-the-U-S.html
                            

                                
Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.

                                
                                
First IV and oral antibiotic with novel mechanism of action approve...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.